Capecitabine and Cisplatin Combination Is an Active and Well-Tolerated Doublet in the Treatment of Metastatic Breast Carcinoma Patients Pretreated with Anthracycline and Taxanes

Abstract

Our aim was to evaluate the activity and toxicity of capecitabine and cisplatin (CapCisp) combination in anthracycline- and taxane-pretreated metastatic breast cancer patients. Thirty-three patients, 20–61 years of age (median 41), were included. They received Cap 2,000 mg/m² on days 1–14 and Cisp 60 mg/m² on day 1, repeated every 3 weeks. Twelve nonprogressive patients continued single-agent Cap therapy until progression or until intolerable toxicity after Cisp cessation. The disease control rate in 154 cycles was 81.8%: complete response 3.0% (n = 1), partial response 48.5% (n = 16) and stable disease 30.3% (n = 10). The median time to disease progression was 6.3 months (95% CI 3.8–8.8). The median overall survival was 11.5 months (95% CI 6.9–16.1). The only grade 3 toxicity was neutropenia, observed in 4 patients (12.1%). CapCisp has an encouraging anti-tumor activity with a low toxicity rate in anthracycline- and taxane-pretreated metastatic breast cancer patients.

A phase II study of capecitabine plus cisplatin in metastatic triple-negative breast cancer patients pretreated with anthracyclines and taxanes

“…The median time interval between last anthracycline-based treatment and the studied regimen was 18 months (range 0-61 months), and the median time interval between last taxanes and the studied combination was 16 months (range 0-61 months). The majority of patients (19,57.6%) had 2 or more metastatic sites, and even more patients (23, 69.7%) had visceral involvement, with lung as the most frequent visceral metastatic site. Most (84.8%) were newly diagnosed metastatic disease at enrollment and received first line XP regimen treatment.…”

“…Altogether, nausea/vomiting were the most common non-hematological toxicities and the incidence in our study appeared to be higher than previous reports. 18,19 Nevertheless, the majority of these events were presented as nausea only, with much less patients complaining about vomiting. Furthermore, most nausea/vomiting events occurred in the first cycle of XP regimen, and decreased with strengthened antiemesis therapy thereafter.…”

“…12,13 Besides, several studies evaluating the association of cisplatin and continuous infusion 5-FU have shown response rate ranging 11-48% in second-or third-line treatment, [14][15][16][17] and 62/ in first-line approach. 14 Additionally, 2 prospective trials 18,19 have obtained interesting results with the combination of cisplatin and capecitabine in unselected MBC patients pretreated with anthracyclines and/or taxanes, indicating an ORR range of 35.9-51.5%, PFS of 5.2-6.3 months and OS of 10.9-11.5 months.…”

Platinum-Based Compounds for the Treatment of Metastatic Breast Cancer

“…The median TTP was 6.3 months and the median OS was 11.5 months. The only grade III toxicity was neutropenia (12.1%) [125]. The second study recruited 39 patients for treatment with cisplatin 20 mg/m 2 every week for 6 weeks, followed by 1 week of rest, and oral capecitabine 1,000 mg/m 2 twice daily for 14 days, followed by a 7-day rest period.…”

Beyond Antiangiogenesis: Intratumorally Injected Bevacizumab Plays a Cisplatin-Sensitizing Role in Squamous Cell Carcinomas in Mice

“…It can cause cross-linking of DNA and induce tumor cell apoptosis [16,17]. Many studies related to cisplatin have focused on how to enhance the effect of cisplatin-induced treatment [18,19,20] on tumor cells and on how to reduce the side effects of cisplatin on normal tissues [21,22]. In this study, we investigated the efficacy of bevacizumab-cisplatin therapy in SCC apart from the anticancer mechanism of bevacizumab.…”